SecBot SecBot
8-K ·Filed Nov 9, 2026

CATX

Perspective Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7d 6h ago SEC0001193125-26-453708
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor the end-of-Phase 2 meeting with the FDA in 1Q 2027 for VMT-α-NET, which is the key catalyst for the stock. The activist stake by Lantheus adds pressure for value creation, so any regulatory or partnership updates could drive significant moves.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

CATX drug pipeline →

bamzireotide

◆ Mixed Named in this 8-K
Impact
Phase
Phase 1/2a
Time to market
At least 3-5 years, assuming a successful End-of-Phase 2 meeting in Q1 2027, a Phase 3 trial initiated in 2027, positive readout, and subsequent FDA filing and review.
Next catalyst
None dated

What to watchWatch for the End-of-Phase 2 meeting outcome with the FDA in Q1 2027, which will determine the Phase 3 trial design and registration path. Positive FDA alignment could re-rate the stock from its deeply depressed levels, while negative feedback or a delayed timeline would add to the execution risks flagged by RBC. The company's ~$100M market cap and likely need for financing to fund a Phase 3 trial create additional overhang.

Price Chart

Loading chart...

Executive Summary

Perspective Therapeutics reported Q3 2026 net loss of $32.4M ($0.27 per share), wider than the $26.0M loss in Q3 2025, driven by increased R&D spending. The company highlighted clinical progress across its radiopharmaceutical pipeline, including FDA Fast Track designation for PSV359 and a collaboration with Merck. Cash runway extends into 2028, but the widening loss and pre-revenue status keep the stock in a development-stage risk profile.

Key Financial Metrics

EPS
−$0.27
Revenue
$20.0K
est $48.0K · -58.3% · -90.4% YoY

Key Facts

  • Net loss for Q3 2026 was $32.4 million, or $0.27 per share, compared to a net loss of $26.0 million, or $0.35 per share, in Q3 2025.
  • Research and development expenses were $26.1 million for Q3 2026, up from $20.3 million in Q3 2025.
  • Cash, cash equivalents, and short-term investments were approximately $202 million as of September 30, 2026, expected to fund operations into 2028.
  • PSV359 received FDA Fast Track Designation for FAP-positive solitary fibrous tumors in October 2026.
  • Entered into a clinical trial collaboration and supply agreement with Merck to evaluate PSV359 in combination with Keytruda for certain lung and colorectal cancers.
  • Targeting an end-of-Phase 2 meeting with the FDA for VMT-α-NET in 1Q 2027.
  • Activist investor Lantheus Holdings disclosed a stake via SC 13D/A filed September 4, 2026, adding context of activist scrutiny.

Financial Impact

Net loss of $32.4M for Q3 2026, up 24.9% from $26.0M in Q3 2025. Cash burn rate increased to ~$34.3M in operating expenses per quarter.

net lossoperating expensescash runway

Risk Factors

  • Pre-revenue clinical-stage company with widening losses and no approved products.
  • Reliance on successful clinical trials and regulatory approvals for pipeline candidates.
  • Activist investor Lantheus may push for strategic changes, creating uncertainty.
  • Cash runway into 2028 depends on maintaining current spending levels and no unforeseen delays.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-453708
Document: catx-20261109.htm0001193125-26-453708
Document: catx-ex99_2.htm0001193125-26-453708
Document: 0001193125-26-453708-index-headers.html0001193125-26-453708
Document: 0001193125-26-453708-index.html0001193125-26-453708
Document: 0001193125-26-453708.txt0001193125-26-453708
8-K Data (Synthetic)0001193125-26-453708

Track record

34 reports on CATX

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +12.27% at T+5 after the Nov 5, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $0.9238 Now $0.9200 −0.41% settles Nov 18
  2. Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $0.9652 Now $0.9200 −4.68% settles Nov 17
  3. Nov 12, 20264d ago SC 13D/A Bearish 6/10 Entry $0.9431 to $0.9238 Now $0.9200 +2.45% ▲ +2.05% +0.13% vs SPY
  4. Nov 10, 20266d ago SC 13G Neutral 2/10 Entry $0.7864 to $0.8252 Now $0.9200 +16.99% ▲ +4.93% +3.62% vs SPY
  5. Nov 9, 20267d ago 8-K Neutral 4/10 Viewing No price data
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.7864 to $0.8252 Now $0.9200 +16.99% ▲ +4.93% +3.62% vs SPY
  7. Nov 6, 202610d ago 8-K Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
  8. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
  9. Nov 6, 202610d ago 8-K Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
  10. Nov 5, 202611d ago Press Release Bullish 6/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (10h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026